Honasa Consumer Limited has announced the termination of its proposed acquisition of a 58% equity stake in Fluence Pharma Private Limited. The decision, effective August 25, 2026, was made due to the non-fulfilment of specified closing conditions under the Share Purchase Agreement. The company remains committed to its nutraceutical strategy and will continue exploring opportunities for growth.
Acquisition Called Off
Honasa Consumer Limited has officially decided to call off its previously announced acquisition of a 58% equity stake in Fluence Pharma Private Limited. The company communicated this decision on August 25, 2026, stating that the acquisition was subject to the completion of certain conditions precedent.
Reason for Termination
The primary reason cited for cancelling the deal is the non-fulfilment of closing conditions as outlined in the Share Purchase Agreement between Honasa Consumer Limited and Fluence Pharma. This termination comes despite an earlier communication on June 23, 2026, which had informed about the proposed stake acquisition.
Future Strategy
Despite this setback in inorganic growth, Honasa Consumer Limited reiterated its commitment to its Nutraceutical strategy. The company stated it will continue to actively evaluate various opportunities, both organic and inorganic, with the aim of building a robust consumer-focused business within the nutraceutical category.
This disclosure was made available on the company’s website, www.honasa.in.
Source: BSE
